Oxford-based SynaptixBio, which is developing an antisense oligonucleotide (ASO) to ‘silence’ the expression of a single mutated gene, says the ASO market is set to grow dramatically, largely because ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback